Insiders Trades
Accuray Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 23 Feb 2026.
Accuray Inc: what insiders have been doing
This page follows insider dealings at Accuray Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 15 insiders published 28 filings.
Not one open-market sale was filed. On the buying side, 2 insiders reported 3 purchases totalling €100k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a purchase of €57k from Mayer Steven F, disclosed on 20 February 2026. Those buying include 1 senior executive and 1 chief executive.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 28 filings, this issuer sits above that mark. The full history, which starts in 2016, counts 11 purchases against 45 sales. The 10-K for the year ended 30 June 2026 shows 401.9 m USD of revenue and -49.2 m USD of net income.
The latest purchase dates back some time: it was published 237 days ago, on 23 February 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
156
Thresholds
n/a
Buy Volume
€416,993
11 ops. · all time
Sell Volume
€1M
45 ops. · all time
Who traded when
BuySaleSteven F. Mayer2 buys
Joseph E. Whitters1 buy
Stephen R. La Neve1 buy
Since the insiders bought
- -37.3%Entry US$0.59 · Close at T+90 US$0.37
- -44.2%Entry US$0.95 · Close at T+90 US$0.53
- -72.4%Entry US$1.23 · Close at T+365 US$0.34
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,140 of 24,148 companies
24.6
score / 100
Value29
Quality21
FCF yld-20%
Earn yld-5.5%
EV/EBITDA10.1x
ROE-101%
Gross mgn32%
Net mgn-0.3%
Debt/EBITDA8.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended June 2025 · cache
US$0.24
Analyst consensus
1 analysts3.00/5
US$0.35Target US$0.35(+44%)US$0.35
Income statement
RevenueUS$458.5M
Gross profitUS$147M32% margin
EBITDAUS$20.2M4% margin
Net income-US$1.6M-10.8% margin
Valuation
PER (forward)-1.1x
P/Book0.7x
Beta1.39
Balance sheet & cash
Market capUS$29M
Total debtUS$176.4M
Free Cash Flow-US$5.7M
Debt / Equity437%
Profitability & ownership
ROE-101.1%
ROA-1.7%
% insiders4.4%
% institutions69.1%
Last declaration on 1 October 2026
Declarations156 total
19,811 shares0Common StockSEC:0001214659-26-012404:0
8,915 shares@ US$0.22550.0069% mcap0.8% of flowCommon StockSEC:0001214659-26-012404:1
54,754 shares@ US$0.3539100.0% of flowCommonSEC144:0001950047-26-005986
40,000 shares@ US$0.38814.4% of flowCommon StockSEC:0001214659-26-004180:0
28,969 shares@ US$0.55100.0% of flowCommon StockSEC:0001214659-26-002732:1
83,723 shares0Common StockSEC:0001214659-26-002732:0
54,875 shares@ US$0.562731.6% of flowCommon StockSEC:0001214659-26-002305:0
Canonical exit: 21 May 2026 (T+90)
126,125 shares@ US$0.532868.4% of flowCommon StockSEC:0001214659-26-002238:0
Canonical exit: 19 May 2026 (T+90)
9,433 shares0Common StockSEC:0001214659-26-000329:0
64,477 shares@ US$1.0218.5% of flowCommon StockSEC:0001214659-25-017523:1
57,341 shares@ US$1.0222.3% of flowCommon StockSEC:0001214659-25-017524:1
895,391 shares0Common StockSEC:0001214659-25-017519:0
50,000 shares0Common StockSEC:0001214659-25-017520:0
50,314 shares0Common StockSEC:0001214659-25-017523:0
44,025 shares0Common StockSEC:0001214659-25-017524:0
56,603 shares0Common StockSEC:0001214659-25-017241:0
56,603 shares0Common StockSEC:0001214659-25-017242:0
56,603 shares0Common StockSEC:0001214659-25-017243:0
45,620 shares0Common StockSEC:0001214659-25-017244:0
56,603 shares0Common StockSEC:0001214659-25-017245:0
56,603 shares0Common StockSEC:0001214659-25-017246:0
56,603 shares0Common StockSEC:0001214659-25-017247:0
22,642 shares@ US$1.056.0% of flowCommon StockSEC:0001214659-25-017242:1
22,642 shares@ US$1.055.3% of flowCommon StockSEC:0001214659-25-017246:1
20,000 shares@ US$0.9705100.0% of flowCommon StockSEC:0001214659-25-016957:0
Canonical exit: 17 Feb 2026 (T+90)
25 of 156 declarations
About Accuray Inc
Accuray Incorporated (ticker: ARAY) is a U.S.-based medical technology company listed on NASDAQ in the United States, focused on precision radiation therapy systems for cancer treatment and neurosurgical radiosurgery. Headquartered in Madison, Wisconsin, Accuray positions itself as a differentiated provider of advanced radiation oncology solutions for hospitals and treatment centers seeking highly targeted delivery for complex cases while also making standard workflows easier to manage. For equity investors, that places the company squarely in the healthcare equipment sub-sector, with exposure to clinical adoption cycles, capital purchasing decisions by providers, and the regulatory environment that governs medical devices. ([accuray.com](https://www.accuray.com/company/))
Founded in 1990, Accuray built its business around two flagship platforms, CyberKnife and TomoTherapy, and has since expanded its portfolio with Radixact, Accuray Precision treatment planning software, and iDMS data management tools. The company designs, manufactures, sells, and services radiation therapy systems and related software, creating a business model that combines higher-value system placements with recurring service revenue tied to the installed base. That mix is strategically important because it can help balance the lumpiness of system orders with more stable service economics over time. ([accuray.com](https://www.accuray.com/company/))
Read moreShow less
Competitive positioning is centered on precision, automation, and clinical versatility. Accuray markets its technology for oncology and neuro-radiosurgery applications and emphasizes its ability to treat difficult-to-address tumors with accuracy. The company’s global footprint is also a defining feature: manufacturing facilities are located in Madison, Wisconsin and Chengdu, China, with regional offices in Switzerland, Japan, China, and Hong Kong. This international presence supports commercialization, but it also introduces meaningful exposure to supply chain disruption, tariffs, foreign exchange volatility, and other cross-border operating risks. ([accuray.com](https://www.accuray.com/company/))
Recent developments matter for the investment case. In August 2025, Accuray reported fiscal fourth-quarter and full-year 2025 results, highlighted service revenue growth, completed debt refinancing, and issued fiscal 2026 guidance. Management guided to total net revenue of $471 million to $485 million and adjusted EBITDA of $31 million to $35 million. The company also pointed to continued progress in customer adoption, product portfolio expansion, and its China joint venture. For investors tracking SEC Form 4 insider activity, the name sits in a small-cap healthcare technology profile where operational execution, balance-sheet management, and international commercialization are all key swing factors. ([investors.accuray.com](https://investors.accuray.com/news-releases/news-release-details/accuray-reports-fourth-quarter-and-fiscal-2025-financial-results))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
